Jim Simons Aveo Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$8.48 - $14.97 $2.47 Million - $4.36 Million	291,400 Added 181.44%	452,000 $6.76 Million
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $245,892 - $324,384	37,200 Added 30.15%	160,600 $1.32 Million
Q2 2022 Aug 12, 2022	BUY	$3.51 - $6.67 $259,037 - $492,246	73,800 Added 148.79%	123,400 $810,000
Q1 2022 May 13, 2022	BUY	$3.15 - $6.01 $156,240 - $298,096	49,600 New	49,600 $277,000
Q3 2021 Nov 12, 2021	SELL	$5.12 - $6.89 $1.15 Million - $1.54 Million	-223,870 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.21 - $7.45 $604,698 - $725,443	97,375 Added 76.98%	223,870 $1.48 Million
Q1 2021 May 13, 2021	BUY	$5.97 - $15.28 $179,070 - $458,323	29,995 Added 31.08%	126,495 $926,000
Q4 2020 Feb 10, 2021	BUY	$5.08 - $6.68 $490,220 - $644,620	96,500 New	96,500 $557,000
Q3 2020 Nov 13, 2020	SELL	$4.16 - $6.26 $269,850 - $406,073	-64,868 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.47 - $9.99 $225,091 - $648,031	64,868 New	64,868 $334,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.